The market for obesity devices in the U.S. is currently dominated by restrictive devices, including primarily adjustible gastric banding (e.g., Allergan's Lap-Band) but also Ethicon Endo-Surgery, Helioscopie, AMI GmbH, Bariatric Solutions GmbH, Cousin Biotech and others.
The future market for these products will also be largely represented by restrictive devices, but in the period from 2011 to 2019 a number of other obesity treatment devices will be added in other categories including artificial fullness devices, malabsorption devices, gastric emptying devices, and appetite suppression devices.
Shown graphically (and drawn from Report #S835) is the current and 2019 U.S. market for devices in the treatment of obesity. As is shown, appetite suppression devices will by 2019 represent the secondmost significant type of obesity device.
See MedMarket Diligence Report #S835: "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019."
Until September 30, 2011, get any MedMarket Diligence report (any option: single user, site license or global license) for 20% off. Order online (or any "online order" link) and use coupon code 1315780157 on checkout to receive a 20% discount.